

Synthesis, Characterisation and X-Ray Structure of Ferrocenyl *N*-Heterocyclic Carbene Complexes of Rhodium(I)

Douglas Onyancha^{1*}, Cedric McClelland² and Thomas Gerber²

¹Dedan Kimathi University of Technology, PO Box 6657-10100, Nyeri, Kenya

²Department of Chemistry, Nelson Mandela Metropolitan University, PO Box 77000, Port Elizabeth 6031, South Africa

Abstract

The synthesis, spectroscopic and structural characterization of Rh(I) ferrocenyl *N*-heterocyclic carbene complexes are described. The *in situ* deprotonation of the imidazolium salts with KOBu^t and subsequent complexation to rhodium(I) proved to be an efficient route for their synthesis yielding good to excellent yields. The X-ray crystal structure of bromo(η^4 -1,5-cyclooctadiene)(1-ferrocenyl-3-propyl-1*H*-imidazol-2-ylidene)rhodium(I) was obtained and reveals substitution disorder of a bromine and chlorine atom on Rh(I) in the ratio of 0.96/0.04.

Keywords: Ferrocenylimidazolium salts; Ferrocenyl *N*-heterocyclic carbene rhodium(I); X-Ray crystal structure

Introduction

Metal-NHC (NHC=*N*-heterocyclic carbenes) complexes were first reported independently in 1968 by Wanzalich and Ofele and the first stable carbene was isolated by Arduengo et al. in 1991 [1]. Since then, NHCs have proved to be a versatile class of ligands in a wide range of metal catalyzed organic transformations [2] and have gained considerable attention as spectator ligands in organometallic chemistry, especially as alternatives to phosphine ligands in homogeneous catalysis [3].

The activity and selectivity of NHC complexes as catalysts can be enhanced by a change of the electronic and steric properties of the 1,3-imidazol-2-ylidene substituents. The substituents can also be used to introduce remote functional groups which can be used to immobilize the catalyst on solid support. While organic substituents have been extensively investigated, the ferrocenyl moiety has not enjoyed the same degree of attention. Sterically, the ferrocenyl moiety represents a relatively bulky group with a unique cylindrical shape and electronically, the powerful donor capacity of ferrocene might be advantageous for additional stabilization of the electron-deficient carbene moiety [4].

N-heterocyclic carbene complexes containing the ferrocenyl moiety were pioneered by Bildstein et al. in 1998. Since then a number of mono and bidentate ferrocenyl-NHC complexes have been reported, many with or without a spacer between the ferrocenyl and the NHC unit [4-11]. It was reported that when the ferrocenyl moiety is attached directly to the carbene, there is a substantial electron donation from the carbene to the metal centre compared to those with a spacer in between [4].

Horvath et al. have reported the synthesis and structural characterization of bis(carbene)gold(I)-ferrocenylphenyl complex [12]. The carbene complex was screened against the human HeLa cervix epithelioid carcinoma cell line, CoLo 320 DM, a human colon adenocarcinoma line, the Jurkat leukaemia cell line and the Jurkat leukaemia breast cancer cell line. It was active against Jurkat leukaemia and its activity was higher than that of cisplatin at lower concentrations.

Chiral ferrocenyl-NHC complexes have also been reported by Bolm et al. [7]. They synthesized a chiral *N*-heterocyclic carbene complex with an oxazolonyl-ferrocenyl substituent linked to rhodium-COD [7]. The compound showed high catalytic reactivity in the hydrosilylation of acetophenone. Chung et al. [13] have synthesized a series of

monodentate ferrocenyl-NHC complexes of rhodium and investigated them for catalytic reduction of 4-methylacetophenone. Although this transformation gave high overall yields (>99%), some of the complexes displayed low stereoselectivities. However, a 52% ee was achieved with a chiral *C*₂-symmetric *N*-heterocyclic carbene complex [13].

In this work, the synthesis and characterization of various ferrocenyl NHC rhodium(I) complexes was carried out successfully via the deprotonation of the ferrocenyl imidazolium salt by a base followed by subsequent complexation by the rhodium centre. Moderate to good yield were obtained. The compounds were characterized by NMR, FT-IR, mass spectrometry and a crystal structure of compound **3** was obtained.

Experimental Methods

All reactions, unless otherwise stated, were performed under an inert atmosphere of dry nitrogen. All reagents, except the ferrocenyl imidazolium salts, were purchased either from Sigma-Aldrich or Fluka and were used as received, unless otherwise stated. The ferrocenyl imidazolium salts were prepared by reacting ferrocenylimidazoles with alkyl halides as described previously. Solvents were freshly dried prior to reaction using standard drying procedures and stored over molecular sieves [14]. Melting points were recorded on an Electrothermal IA 900 series digital melting point apparatus and are uncorrected. Infrared spectra were recorded on a DigiLab FTS 3100 Excalibur HE spectrophotometer as KBr disks. ¹H and ¹³C NMR spectra were recorded on a Bruker Avance 300 MHz spectrometer as solutions in CDCl₃ using TMS as an internal standard. Mass spectra were recorded on a VG-70SE mass spectrometer at the University of Witwatersrand in Johannesburg. X-ray analysis was done at the Ludwig-Maximilians University, Munich.

***Corresponding author:** Douglas Onyancha, Dedan Kimathi University of Technology, PO Box 6657-10100, Nyeri, Kenya, Tel: +254712982910; Fax: +254712982910; E-mail: Douglas.onyancha@dkut.ac.ke

Received December 16, 2015; **Accepted** December 18, 2015; **Published** January 02, 2016


Citation: Onyancha D, McClelland C, Gerber T (2016) Synthesis, Characterisation and X-Ray Structure of Ferrocenyl *N*-Heterocyclic Carbene Complexes of Rhodium(I). Chem Sci J 7: 117. doi:[10.4172/2150-3494.1000117](https://doi.org/10.4172/2150-3494.1000117)

Copyright: © 2016 Onyancha D, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Synthesis of ferrocenyl NHC-rhodium(I) [(NHC)Rh(COD) X] complexes


General procedure: [Rh(cod)Cl]₂ (1.0 eq.) and KOBu^t (2.2 eq.) were placed in a two-necked round-bottomed flask on a Schlenk line and THF (20 cm³) was added under an atmosphere of argon, and stirred for 45 minutes at room temperature. To this mixture was added the appropriate imidazolium salt (2.2 eq.). The reaction mixture was stirred for 3 hours at room temperature, filtered and the filtrate concentrated under vacuum. The resulting residue was dissolved in dichloromethane and subjected to column chromatography using silica gel as stationary phase and dichloromethane as eluent. Removal of the solvent under reduced pressure provided the product.

Iodo(η⁴-1,5-cyclooctadiene)(1-ferrocenyl-3-methyl-1H-imidazol-2-ylidene)rhodium(I) (1):




[Rh(COD)Cl]₂ (50 mg, 0.1 mmol); KOBu^t (25 mg, 0.223 mmol); 1-ferrocenyl-3-methyl-1H-imidazolium iodide (88 mg, 0.223 mmol). Yield (106 mg, 88%) of a yellow powder; m.p. 185-185°C; IR (KBr cm⁻¹): 3098, 2935, 2872, 2827, 1556, 1497, 1282, 1238, 1105, 832, 728; ¹H NMR (CDCl₃): 7.31 (1H, d, *J* 2.0, NCH=NCH), 6.95 (1H, d, *J* 2.0 NCH=NCH), 5.22 (2H, br, CH-COD), 4.37 (2H, br, C₅H₄), 4.29 (2H, br, C₅H₄), 4.26 (5H, s, C₅H₅), 4.07 (3H, s, CH₃), 3.34 (1H, m, CH-COD), 2.99 (1H, m, CH-COD), 2.26 (2H, m, CH₂-COD), 1.89 (2H, m, CH₂-COD); ¹³C NMR (CDCl₃): 182.90 [d, *J*_{Rh-C} 49.06, C(carbene)], 122.30, 121.83, 96.98, 95.67 (d, *J*_{Rh-C} 7.03), 95.04 (d, *J*_{Rh-C} 6.68), 72.09 (d *J*_{Rh-C} 14.05), 70.96 (d *J*_{Rh-C} 14.26), 69.79, 67.40, 65.77, 65.62, 61.26, 39.04, 32.63, 31.49, 29.69, 29.43; *m/z* (APCI) 477 (M⁺-I 100%).

Iodo(η⁴-1,5-cyclooctadiene)(3-ethyl-1-ferrocenyl-1H-imidazol-2-ylidene)rhodium(I) (2):




[Rh(COD)Cl]₂ (25 mg, 0.05 mmol); KOBu^t (13 mg, 0.115 mmol); 3-ethyl-1-ferrocenyl-1H-imidazolium iodide (47 mg, 0.115 mmol). Yield (46 mg, 73%) of a yellow powder; m.p. 206-208°C; IR (KBr cm⁻¹): 2937, 2870, 1545, 1499, 1411, 1295, 1241, 1105, 998, 868, 730; ¹H NMR (CDCl₃): 7.33 (1H, d, *J* 2.0, NCH=NCH), 6.99 (1H, d, *J* 2.0, NCH=NCH), 5.25-5.17 (2H, m, 2 × CH-COD), 4.6 (2H, q, *J* 9, CH₂) 4.34 (2H, b, C₅H₄), 4.27 (5H, s, C₅H₅), 4.18 (2H, br, C₅H₄), 3.33 (1H, m, CH-COD), 2.98 (1H, m, CH-COD), 2.25 (4H, m, CH₂-COD), 1.85 (4H, m, CH₂-COD), 1.55 (3H, t, *J* 7.4, CH₃); ¹³C NMR (CDCl₃): 182.11 [d *J*_{Rh-C} 49.06, C(carbene)], 122.36, 119.65, 97.21, 95.36 (d, *J*_{Rh-C} 7.10), 94.95 (d, *J*_{Rh-C} 7.09), 72.35 (d, *J*_{Rh-C} 14.18), 71.12 (d, *J*_{Rh-C} 14.21), 69.75, 67.52, 65.75, 65.62, 32.60, 31.45, 29.70, 29.30, 15.39; *m/z* (APCI) 491 (M⁺ 100%).

Bromo(η⁴-1,5-cyclooctadiene)(1-ferrocenyl-3-propyl-1H-imidazol-2-ylidene)rhodium(I) (3):




[Rh(COD)Cl]₂ (41 mg, 0.083 mmol); KOBu^t (20.5g mg, 0.183 mmol); 1-ferrocenyl-3-propyl-1H-imidazolium iodide (68.5 mg, 0.183 mmol). Yield (51 mg, 52%) of a yellow powder; m.p. 205-206°C; IR (KBr cm⁻¹): 2931, 2869, 1569, 1499, 1407, 1295, 1241, 1105, 998, 868, 736; ¹H NMR (CDCl₃): 7.31 (1H, d, *J* 2.0, NCH=NCH), 6.96 (1H, d, *J* 2.0, NCH=NCH), 5.08 (2H, br, CH-COD), 4.43 (2H, br, C₅H₄), 4.25 (5H, s, C₅H₅), 4.22 (2H, br, C₅H₄), 3.19 (1H, m, CH-COD), 2.85 (1H, m, CH-COD), 2.25 (4H, br, CH₂-COD), 1.84 (6H, m, CH₂-COD + CH₂) 1.11 (3H, t, *J* 7.4, CH₃); ¹³C NMR (CDCl₃): 182.90 [d, *J*_{Rh-C} 50.57, C(carbene)], 122.14, 120.11, 97.52, 96.81 (d, *J*_{Rh-C} 7.13), 96.34 (d *J*_{Rh-C} 6.98), 70.03 (d, *J*_{Rh-C} 14.37), 69.72, 68.55 (d, *J*_{Rh-C} 14.40), 68.26, 65.83, 65.69, 32.78, 32.77, 31.98, 31.04, 29.12, 28.99, 23.75, 11.59; *m/z* (APCI) 506 (M⁺-Br 100%).

Bromo(η⁴-1,5-cyclooctadiene)(1-ferrocenyl-3-propan-2-yl-1H-imidazol-2-ylidene)rhodium(I) (4):



[Rh(COD)Cl]₂ (48 mg, 0.097 mmol); KOBu^t (24 mg, 0.213 mmol); 1-ferrocenyl-3-(propan-2-yl)-1H-imidazolium bromide (79 mg, 0.213 mmol). Yield (71 mg, 73%) of a yellow powder; m.p. 242-243°C; IR (KBr cm⁻¹): 2929, 2870, 1501, 1408, 1311, 1230, 1123, 1103, 1009, 867, 725; ¹H NMR (CDCl₃): 7.32 (1H, d, *J* 2.0, NCH=NCH), 6.96 (1H, d, *J* 2.0, NCH=NCH), 5.15 (1H, m, CH-COD), 5.01 (1H, m, CH-COD), 4.32 (2H, t, *J* 1.5, C₅H₄), 4.26 (5H, s, C₅H₅), 4.21 (2H, t, *J* 1.5, C₅H₄), 3.25 (1H, m, CH-COD), 2.82 (1H, m, CH-COD), 2.27 (4H, m, CH₂-COD), 1.87 (4H, m, CH₂-COD), 1.52 (6H, t, *J* 9.5, CH₃); ¹³C NMR (CDCl₃): 181.86 [d, *J*_{Rh-C} 50.57, C(carbene)], 122.65, 116.42, 97.66, 96.60 (d, *J*_{Rh-C} 7.09), 96.46 ((d, *J*_{Rh-C} 7.18), 69.69, 69.40 (d, *J*_{Rh-C} 14.42), 68.29, 65.81, 65.67, 33.23, 31.55, 29.36, 28.65, 23.51; *m/z* (APCI) 506 (M⁺-Br 100%).


Iodo(η⁴-1,5-cyclooctadiene)(3-butyl-1-ferrocenyl-1H-imidazol-2-ylidene)rhodium(I) (5):



[Rh(COD)Cl]₂ (52 mg, 0.106 mmol); KOBu^t (26 mg, 0.234 mmol); 3-butyl-1-ferrocenyl-1H-imidazolium iodide (102.0 mg, 0.234 mmol). Yield (112 mg, 83%) of a yellow powder; m.p. 226-227°C; IR (KBr cm⁻¹): 2934, 2874, 1650, 1529, 1459, 1413, 1243, 1106, 1003, 819, 728; ¹H NMR (CDCl₃): 7.32 (1H, d, *J* 1.9, NCH=NCH), 6.97 (1H, d, *J* 2.0, NCH=NCH), 5.21 (2H, br, CH-COD), 4.74 (2H, br, CH₂), 4.45(2H, C₅H₄), 4.26 (5H, s, C₅H₅), 4.19 (2H, m, C₅H₄), 3.31 (1H, m, CH-COD),


2.25 (4H, m, CH₂-COD), 1.89 (4H, m, CH₂-COD), 1.52 (2H, m, CH₂), 1.06 (3H, t, J 7.3, CH₃); ¹³C NMR (CDCl₃): 182.13 [d, J_{Rh-C} 49.06, C(carbene)], 122.0, 120.20, 97.23, 95.41 (d, J_{Rh-C} 7.10), 94.70 (d, J_{Rh-C} 6.89), 72.58 (d, J_{Rh-C} 14.17), 70.87 (d, J_{Rh-C} 14.19), 69.76, 67.59, 65.74, 65.60, 61.41, 51.69, 32.23, 31.26, 29.74, 29.37, 20.24, 13.96; *m/z* (APCI) 519 (M⁺-I 100%).

Bromo(η⁴-1,5-cyclooctadiene)(3-benzyl-1-ferrocenyl-1H-imidazol-2-ylidene)rhodium(I) (6):




[Rh(COD)Cl]₂ (22.4 mg, 0.046 mmol); KOBu^t (11.2 mg, 0.10 mmol); 3-benzyl-1-ferrocenyl-1H-imidazolium iodide (42.3 mg, 0.10 mmol). Yield (54 mg, 92%) of a yellow powder; m.p. 207-208°C; IR (KBr cm⁻¹): 2932, 2875, 1650, 1500, 1407, 1231, 1118, 998, 870, 708; ¹H NMR (CDCl₃): 7.43 (5H, m, ArH), 7.30 (1H, d, J 2.0, NCH=CHN), 6.78 (1H, d, J 2, NCH=CHN), 5.13 (2H, m, 2 × CH-COD), 4.34 (2H, br, C₅H₄), 4.27 (5H, s, C₅H₅), 4.24 (2H, br, C₅H₄), 3.16 (1H, m, CH-COD), 2.92 (1H, m, CH-COD); ¹³C NMR (CDCl₃): 183.76 [d, J_{Rh-C} 50.57, C(carbene)], 136.22, 128.93, 128.46, 128.18, 122.34, 120.57, 97.32 (d, J_{Rh-C} 7.00), 96.47 (d, J_{Rh-C} 7.11), 70.28 (d, J_{Rh-C} 14.45), 69.78, 69.73, 68.92 (d, J_{Rh-C} 14.44), 68.14, 65.90, 61.50, 32.51, 32.16, 29.19, 28.33; *m/z* (APCI) 553 (M⁺-Br⁻ 100%).

Iodo(η⁴-1,5-cyclooctadiene)[1-(4-ferrocenylphenyl)-3-methyl-1H-imidazol-2-ylidene]rhodium(I) (7):




[Rh(COD)Cl]₂ (25 mg, 0.1 mmol); KOBu^t (24.7 mg, 0.22 mmol); 1-(4-ferrocenylphenyl)-3-methyl-1H-imidazolium iodide (52.4 mg, 0.22 mmol). Yield (60 mg, 88%) of a yellow powder; m.p. 252-253°C; IR (KBr cm⁻¹): 2933, 2875, 1650, 1530, 1459, 1255, 1104, 1072, 1006, 887, 723; ¹H NMR (CDCl₃): 8.12 (2H, d, J 8.3, ArH), 7.64 (2H, d, J 8.3, ArH), 7.19 (1H, d, J 1.9, NCH=CHN), 7.03 (1H, d, J 1.8, NCH=CHN), 5.32 (1H, br, CH-COD), 5.19 (1H, br, CH-COD), 4.75 (2H, t, J 1.4, C₅H₄), 4.41 (2H, t, J 1.4, C₅H₄), 4.15 (3H, s, CH₃), 4.09 (5H, s, C₅H₅), 3.47 (1H, m, CH-COD), 2.87 (1H, m, CH-COD), 2.22 (4H, m, CH₂-COD), 1.78 (4H, m, CH₂-COD); ¹³C NMR (CDCl₃): 182.64 [d, J_{Rh-C} 50.57, C(carbene)], 139.25, 137.89, 125.93, 124.32, 122.80, 121.36, 95.90 (d, J_{Rh-C} 6.79), 95.77 (d, J_{Rh-C} 7.55), 83.92, 71.51 (d, J_{Rh-C} 14.34), 71.17 (d, J_{Rh-C} 14.34), 69.73, 69.40, 66.59, 39.27, 33.19, 31.19, 30.34, 28.94; *m/z* (APCI) 553 (M⁺-I 100%).

Iodo(η⁴-1,5-cyclooctadiene)[3-ethyl-1-(4-ferrocenylphenyl)-1H-imidazol-2-ylidene]rhodium(I) (8):




[Rh(COD)Cl]₂ (50 mg, 0.1 mmol); KOBu^t (24.7 mg, 0.22 mmol); 3-ethyl-1-(4-ferrocenylphenyl)-1H-imidazolium iodide (108 mg, 0.22 mmol). Yield (53 mg, 72%) of a yellow powder; m.p. 203-205°C; IR (KBr cm⁻¹): 2932, 2870, 1635, 1529, 1415, 1257, 1103, 995, 823; ¹H NMR (CDCl₃): 8.15 (2H, d, J 8.6, 2 × ArH), 7.64 (2H, d, J 8.6, 2 × ArH), 7.21 (1H, d, J 2.0, NCH=CHN), 7.06 (1H, d, J 2.0, NCH=CHN), 5.32 (1H, br, CH-COD), 5.17 (1H, br, CH-COD), 4.63-4.76 (4H, br, 2 × C₅H₄ and N-CH₂), 4.40 (2H, t, J 1.9, 2 × C₅H₄), 4.09 (5H, s, C₅H₅), 3.45 (1H, br, CH-COD), 2.87 (1H, br, CH-COD), 2.28 (4H, br, CH₂-COD), 1.85 (4H, br, CH₂-COD), 1.60 (3H, t, J 7.1, CH₃); ¹³C NMR (CDCl₃): 181.85 [d, J_{Rh-C} 49.82, C(carbene)], 139.19, 138.05, 125.93, 124.40, 121.84, 120.21, 95.63 (d, J_{Rh-C} 6.79), 94.41 (d, J_{Rh-C} 6.80), 83.96, 72.09 (d, J_{Rh-C} 14.21), 71.18 (d, J_{Rh-C} 14.12), 69.39, 66.60, 66.51, 51.85, 32.78, 31.39, 29.72, 29.22, 15.48; *m/z* (APCI) 567 (M⁺-I 100%).

Bromo(η⁴-1,5-cyclooctadiene)[1-(4-ferrocenylphenyl)-3-propyl-1H-imidazol-2-ylidene]rhodium(I) (9):



[Rh(COD)Cl]₂ (25 mg, 0.05 mmol); KOBu^t (13.5 mg, 0.12 mmol); 1-(4-ferrocenylphenyl)-3-propyl-1H-imidazolium bromide (52 mg, 0.12 mmol). Yield (60 mg, 91%) of a yellow powder; m.p. 206-207°C; IR (KBr cm⁻¹): 2935, 2875, 1529, 1459, 1413, 1243, 1106, 1077, 1002, 819, 728, 698; ¹H NMR (CDCl₃): 8.13 (2H, d, J 8.3, ArH), 7.65 (2H, d, J 7.98, ArH), 7.17 (1H, d, J 1.9, NCH=NCH), 7.03 (1H, d, J 1.9, NCH=NCH), 5.19 (1H, m, CH-COD), 5.05 (1H, m, CH-COD), 4.76 (2H, br, C₅H₄), 4.40 (2H, br, C₅H₄), 4.09 (5H, s, C₅H₅), 3.30 (1H, m, CH-COD), 2.77 (1H, m, CH-COD), 2.33 (2H, m, CH₂-COD), 2.13 (2H, m, CH₂-COD), 1.99 (2H, m, CH₂), 1.81 (4H, br, CH₂-COD), 1.14 (3H, t, J 7.4, CH₃); ¹³C NMR (CDCl₃): 182.33 [d, J_{Rh-C} 49.82, C(carbene)], 139.22, 138.12, 126.03, 124.71, 124.61, 121.35, 120.77, 97.04 (d, J_{Rh-C} 6.88), 96.90 (d, J_{Rh-C} 6.93), 84.04, 69.73, 69.48 (d, J_{Rh-C} 14.34), 68.92 (d, J_{Rh-C} 14.61), 66.62, 66.55, 53.23, 33.17, 31.73, 28.26, 28.75, 11.60; *m/z* (APCI) 581 (M⁺-Br⁻ 100%).


Bromo(η⁴-1,5-cyclooctadiene)[1-(4-ferrocenylphenyl)-3-propan-2-yl-1H-imidazol-2-ylidene]rhodium(I) (10):



[Rh(COD)Cl]₂ (25 mg, 0.05 mmol); KOBu^t (13.5 mg, 0.12 mmol); 1-(4-ferrocenylphenyl)-3-(propan-2-yl)-1H-imidazolium bromide (52 mg, 0.12 mmol). Yield (56 mg, 85%) as a yellow powder; m.p. 216-218°C; IR (KBr cm⁻¹): 2932, 2872, 1530, 1460, 1414, 1226, 1106, 1003, 816, 733, 699; ¹H NMR (CDCl₃): 8.12 (2H, d, J 8.4, ArH), 7.65 (2H, d, J 8.4, ArH), 7.17 (1H, d, J 1.8, NCH=CHN), 7.05 (1H, d, J 1.8, NCH=CHN), 5.23 (1H, m, CH-COD), 5.02 (1H, m, CH-COD), 4.75 (2H, t, J 1.7, C₅H₄), 4.40 (2H, t, J 1.7, C₅H₄), 4.09 (5H, s, C₅H₅), 3.38 (1H, m, CH-COD), 2.72 (1H, m, CH-COD), 2.31 (4H, m, CH₂-COD), 1.86 (4H, m, CH₂-COD), 1.60 (6H, d, J 8.8, 2 × CH₃); ¹³C NMR (CDCl₃): 180.95 [d, J_{Rh-C} 50.56, C(carbene)], 139.15, 138.15, 126.07, 124.55, 121.81, 117.13, 97.10 (d, J_{Rh-C} 6.99), 96.73 (d, J_{Rh-C} 6.96), 84.05, 69.73, 69.38, 69.21, 68.82 (d,


$J_{\text{Rh-C}}$ 14.41), 66.60, 53.38, 33.56, 31.35, 29.62, 28.34, 23.71; m/z (APCI) 581 ($M^+ - \text{Br}$ 100%).

Iodo(η^4 -1,5-cyclooctadiene)[3-butyl-1-(4-ferrocenylphenyl)-1H-imidazol-2-ylidene]rhodium(I) (11):



$[\text{Rh}(\text{COD})\text{Cl}]_2$ (25 mg, 0.05 mmol); KOBU^+ (13.5 mg, 0.12 mmol); 3-butyl-1-(4-ferrocenylphenyl)-1H-imidazolium iodide (52 mg, 0.12 mmol). Yield (69 mg, 89%) of a yellow powder; m.p. 215-217°C; IR (KBr cm^{-1}): 2932, 1528, 1459, 1412, 1223, 1106, 1077, 1003, 819, 726; ^1H NMR (CDCl_3): 8.16 (2H, d, J 8.6, ArH), 7.64 (2H, d, J 8.6, ArH), 7.20 (1H, d, J 2.0, NCH=NCH), 7.05 (1H, d, J 2.0, NCH=NCH), 5.30 (1H, m, CH-COD), 5.20 (1H, m, CH-COD), 4.75 (2H, t, J 1.9, C_5H_4), 4.40 (2H, t, J 1.9, C_5H_4), 4.09 (5H, s, C_5H_5), 3.42 (1H, br, CH-COD), 2.91 (1H, br, CH-COD), 2.29 (2H, m, CH_2 -COD), 2.11 (2H, m, CH_2 -COD), 1.89 (4H, m, CH_2 -COD), 1.57 (2H, m, CH_2), 1.08 (3H, t, J 7.3, CH_3); ^{13}C NMR (CDCl_3): 181.73 [d, $J_{\text{Rh-C}}$ 49.06, C(carbene)], 139.17, 138.08, 125.92, 124.44, 121.66, 120.77, 95.64 (d, $J_{\text{Rh-C}}$ 6.79), 95.42 (d, $J_{\text{Rh-C}}$ 6.79), 83.87, 72.10 (d, $J_{\text{Rh-C}}$ 13.87), 71.19 (d, $J_{\text{Rh-C}}$ 14.12), 69.39, 66.60, 66.51, 51.85, 32.76, 32.311, 31.39, 29.72, 29.23, 20.24, 13.99; m/z (APCI) 595 ($M^+ - \text{I}$ 60%).

Bromo(η^4 -1,5-cyclooctadiene)[3-benzyl-1-(4-ferrocenylphenyl)-1H-imidazol-2-ylidene]rhodium(I) (12):



$[\text{Rh}(\text{COD})\text{Cl}]_2$ (25 mg, 0.05 mmol); KOBU^+ (12.3 mg, 0.11 mmol); 3-benzyl-1-(4-ferrocenylphenyl)-1H-imidazolium bromide (57.4 mg, 0.11 mmol). Yield (57.2 mg, 75%) of a yellow powder; m.p. 234-235°C; IR (KBr cm^{-1}): 2934, 2824, 1651, 1528, 1456, 1409, 1232, 1106, 1077, 997, 816, 708; ^1H NMR (CDCl_3): 8.17 (2H, d, J 8.5, ArH), 7.67 (2H, d, J 8.6), 7.51-7.35 (5H, m, ArH), 7.17 (1H, d, J 2.0, NCH=NCH), 6.86 (1H, d, J 1.9, NCH=NCH) 6.05 (1H, d, J 14.86, CH_2), 5.81 (1H, d, J 14.86), 5.21 (1H, m, CH-COD), 5.09 (1H, m, CH-COD), 4.76 (2H, t, J, 1.8 C_5H_4), 4.41 (2H, t, J 1.8 C_5H_4), 4.06 (5H, s, C_5H_5), 3.26 (1H, m, CH-COD), 2.80 (1H, m, CH-COD), 2.19 (4H, m, CH_2 -COD), 1.72 (4H, m CH_2 -COD); ^{13}C NMR (CDCl_3): 183.16 [d, $J_{\text{Rh-C}}$ 49.82, C(carbene)], 139.38, 137.99, 136.20, 128.94, 128.65, 128.25, 126.08, 121.60, 121.55, 121.20, 97.57 (d, $J_{\text{Rh-C}}$ 6.8), 97.05 (d, $J_{\text{Rh-C}}$ 6.79), 83.98, 69.94 (d, $J_{\text{Rh-C}}$ 14.47), 69.73, 69.41, 69.22 (d, $J_{\text{Rh-C}}$ 14.47), 66.62, 66.57, 32.83, 31.93, 29.03, 28.87; m/z (APCI) 629 ($M^+ - \text{Br}$ 80%).

X-ray crystallography

X-ray diffraction data for the rhodium-NHC complex 3 was collected on an Oxford Xcalibur diffractometer with graphite-monochromated Mo K α radiation at 173 (2) K. The collection method involved ω -scan of width 0.3°. Data collection, data reduction and refinement were performed with the program CrysAlisPro [15]. The crystal structures were solved by direct method, using the program SHELXS-97 [16]. Crystal structure refinement was carried out by SHELXL-97 [16]. Molecular graphics were generated by ORTEP-3 for Windows [17] and Mercury [18-21].

Results and Discussion


We have synthesized a series of ferrocenyl-NHC-Rh(I)(COD) (X) carbene complexes from appropriate ferrocenylimidazolium salts and $[\text{Rh}(\text{COD})\text{Cl}]_2$. The *in situ* deprotonation of the imidazolium salt with a base, and trapping the carbene with rhodium(I), was the synthetic route employed in the formation of the NHC complexes in this study. The dimeric chloro-bridged rhodium complex $[\text{Rh}(\text{COD})\text{Cl}]_2$, KOBU^+ , and the corresponding imidazolium salts in THF under argon were stirred for 3h at room temperature. The resulting solution was concentrated and chromatographed on a column (silica gel, dichloromethane), affording the Rh-NHC complexes in good to excellent yields (Scheme 1).

The Rh-NHC complexes were characterized using IR, ^1H NMR, ^{13}C NMR, mass spectrometry and X-ray crystallography.

The ^1H NMR and ^{13}C NMR spectral data of the complexes, along with their assignments, are recorded in the experimental section. The ^1H NMR spectra display two doublets at 7.0 and 7.2 ppm ($J \sim 2.0$), corresponding to the NCH=CHN unit of the imidazol-2-ylidene. The spectra also reveal the disappearance of the C2(H) peak which normally appears at about 10 ppm for the imidazolium salts. The absence of the peak indicates that coordination to rhodium takes place at C(2). The signals of the protons of the bound imidazol-2-ylidene ring appear at higher field than those of the unbound ring, further indicating its coordination. From the ^1H NMR spectrum, the four CH protons on the 1,5-cyclooctadiene (COD) ring are not equivalent (giving four signals at 5.15, 5.0, 3.25 and 2.9 ppm) which may be attributed to the spatial orientation of the COD.

A comparison of the ^1H NMR chemical shifts of the N-ferrocenyl group of the imidazole-2-ylidene with those of the 4-ferrocenylphenyl group assisted in the evaluation of the effect of a spacer group. There was a small difference in their chemical shift values which may be due to the presence of the spacer group between the imidazol-2-ylidene and ferrocene. In the absence of the spacer, the protons were shifted more upfield, implying some deshielding. However, this shift is insignificant, since the linking system is conjugated and a large chemical shift difference is not expected.

The ^{13}C NMR spectrum shows the signal of the metalated carbon as a doublet between 181 and 183 [$J_{\text{Rh-C}}$ 49 C(carbene)]. Other characteristic doublets were observed around at 95.90 ($J_{\text{Rh-C}}$ 6.8), 95.70 ($J_{\text{Rh-C}}$ 7.7), 71.51 ($J_{\text{Rh-C}}$ 14.34) and 71.17 ($J_{\text{Rh-C}}$ 14.34).



The crystal structure of the rhodium complex **3** (Figure 1) was obtained with a single crystal grown from a mixture of dichloromethane and toluene. The ORTEP diagram of the molecule, showing its atom-numbering scheme, is shown in Figure 1. The complex crystallizes in the monoclinic space group $P2_1/n$ with $Z = 4$. Least-squares refinement of the structure gave a final R factor of 0.0331. Details of crystal and structure refinement data are summarized in Table 2, while selected bond angles, bond lengths and torsion angles are listed in Table 1.

The structure exhibits a square planar geometry around the Rh(I) centre, with the imidazolylidene ring nearly perpendicular to the coordination plane as deduced from the torsional Br(1)-Rh(1)-C(1)-N(1) and Br(1)-Rh(1)-C(1)-N(2) angles of $-88.26(2)^\circ$ and $93.07(2)^\circ$, respectively. The Rh-C(carbene) bond length of 2.0189(17) Å is in the range of a single bond. The average COD-Rh bond lengths are 2.1143 Å (*trans* to bromine) and 2.1571 Å (*trans* to imidazolylidene ring).

The X-ray determination of **3** was also useful as it reveals substitutional disorder of the bromine and chlorine atom on Rh(I) in the ratio of 0.96/0.04. The disorder arises from the reactants employed in the synthesis of Rh-NHC complex, 1-ferrocenyl-3-propyl-1*H*-imidazolium bromide and [Rh(COD)Cl]₂ which contained the bromide and the chloride atoms respectively. The packing diagram of **3** (Figure 2) shows that the molecules are arranged in a head-to-head conformation in the unit cell. The synthesis of an array of new ferrocenyl NHC complexes of rhodium (I). It is worthwhile to note that the yield of the compounds did not follow any particular pattern or depended on the substituent groups present. The simplicity, efficiency and milder conditions of this method makes it the synthetic route of choice for these reactions.




Figure 1: Crystal structure of bromo (η^4 -1,5-cyclooctadiene)(1-ferrocenyl-3-propyl-1*H*-imidazol-2-ylidene)rhodium(I).




Figure 2: Crystal structure packing diagram for compound **3** viewed down the b -axis.

Bond length		Angle	
Rh(1)-C1	2.019(2)	Br(1)-Rh(1)-C(1)	90.66(5)
Rh(1)-Br	2.516(3)	N(1)-C(1)-N(2)	103.73(2)
Rh(1)-C(17)	2.120(2)	N(1)-C(7)-C(1)	123.91(2)
Rh(1)-C(18)	2.109(2)	C(3)-N(1)-C(1)	110.69(2)
Rh(1)-C(21)	2.212 (2)	C(3)-N(1)-C(7)	125.42(2)
Rh(1)-C(22)	2.203(2)	C(2)-N(2)-C(1)	111.53(2)
Rh(1)-Cl(1)	2.370(5)	C(3)-C(2)-N(2)	106.9(2)
N(1)-C(1)	1.368(2)	C(2)-C(3)-N(1)	107.2(2)
N(1)-C(3)	1.387(2)	Br(1)-Rh(1)-C(1)-N(1)	-88.26(2)
N(2)-C(2)	1.379(2)	Br(1)-Rh(1)-C(1)-N(2)	93.07(2)
N(2)-C(4)	1.471(2)		
N(1)-C(7)	1.427(2)		
C(2)-C(3)	1.335(3)		

Table 1: Selected bond lengths (Å) and angles ($^\circ$) of compound **3**.

3	
Empirical formula	C ₂₄ H ₃₀ Br _{0.96} Cl _{0.04} FeN ₂ Rh
Formula weight	583.385
Temperature (K)	173(2)
Wavelength (Å)	0.71073
Crystal system	Monoclinic
Space group	P2 ₁ /n
Unit cell dimensions	
$a/\text{Å}$	10.295(3)
$b/\text{Å}$	11.492(3)
$c/\text{Å}$	19.119(5)
$\beta/^\circ$	107.565(5)
Volume (Å ³)	2239.75(1)
Z	4
Density (calculated) g/cm ³	1.7301(8)
Absorption coefficient (mm ⁻¹)	3.11
$F(000)$	1172
Crystal size (mm ³)	0.28 × 0.23 × 0.20
Reflections measured	9834
Reflections unique	4529[R(int) = 0.026]
Theta range for data collection ($^\circ$)	4.28-26.32
Limiting indices	-12 ≤ h ≤ 12
	-13 ≤ k ≤ 14
	-16 ≤ l ≤ 23
Goodness-of-fit on F^2	0.9
Data/restraints/parameters	4529/0/268
Final R indices	R1=0.260
	wR2=0.052
Largest diff. peak and hole (eÅ ⁻³)	0.516, -0.444

Table 2: Crystal data and structure refinement for compound **3**.

Conclusion

Novel ferrocenylimidazol-2-ylidene-rhodium complexes have been synthesized from ferrocenylimidazolium salts and [Rh(COD)Cl]₂. These carbene complexes have been characterized by IR, NMR, mass spectrometry and X-ray crystal structure analysis. The use of an *in situ* deprotonation method and trapping the resultant carbene with the rhodium metal centre proved efficient and straightforward.

Supplementary Material

CCDC 764293 contains the supplementary crystallographic data for compound **3**. The data can be obtained free of charge

via <http://www.ccdc.cam.ac.uk/cots/retrieving.html>, or from the Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK, Fax: (+44)1223-336-033; E-mail: deposit@ccdc.cam.ac.uk.

Acknowledgements

We are grateful the Nelson Mandela Metropolitan University and the National Research Fund (NRF) for financial support.

References

- Nolan SP (2006) N-Heterocyclic Carbenes in Synthesis. Wiley-Vch, Weinheim, Germany.
- Garrison JC, Youngs WJ (2005) Ag(I) N-heterocyclic carbene complexes: synthesis, structure and application. Chem Rev 105: 3978-4008.
- Nichol GS, Rajaseelan J, Anna LJ, Rajaseelan E (2009) N-Heterocyclic Carbene Complexes of Rhodium and Iridium: Steric Effects on Molecular Conformation. Eur J Inorg Chem. pp: 4320-4328.
- Bildstein B, Maluan M, Kopacka H, Wurst K, Mitterböck M, et al. (1999) N,N'-Diferrocenyl-N-heterocyclic Carbenes and Their Derivatives. Organometallics 18: 4325-4336.
- Bildstein B, Malaun M, Kopacka H, Ongania KH, Wurst K (1999) N-Heterocyclic carbenes with N-ferrocenyl-N'-methyl-substitution: synthesis, reactivity, structure and electrochemistry. J Organomet Chem 572: 177-187.
- Bretogg A, Camponovo F, Togni A (2005) N-Ferrocenyl-Substituted Planar-Chiral N-Heterocyclic Carbenes and Their PdII Complexes. Eur J Inorg Chem. pp: 347-356.
- Visentin F, Togni A (2007) Synthesis and Characterization of Palladium(II) π -Allyl Complexes with Chiral Phosphinocarbene Ligands. Kinetics and Mechanism of Allylic Amination. Organometallics 26: 3746-3754.
- Togni SG (2005) A Dinuclear Copper(I) Complex Containing a Bridging Chiral Tridentate Carbene Ligand. Organometallics 24: 203-205.
- Bolm MK, Raabe G (2002) The First Planar-Chiral Stable Carbene and Its Metal Complexes. Organometallics 21: 707-710.
- Shi JC, Yang PY, Tong Q, Wu Y, Peng Y (2006) Highly efficient and stable palladium/imidazolium salt-phosphine catalysts for Suzuki-Miyaura cross-coupling of aryl bromides. J Mol Catal A: Chem 259: 7-10.
- Shi JC, Yang PY, Tong Q, Jia L (2008) Palladium-catalyzed aminations of aryl halides with phosphine-functionalized imidazolium ligands. Dalton Trans. pp: 938-945.
- Coleman KS, Turberville S, Pascu SI, Green MLH (2005) Synthesis of a new bidentate ferrocenyl N-heterocyclic carbene ligand precursor and the palladium (II) complex trans-[PdCl₂(C₁fc₁C)], where (C₁fc₁C)=1,1'-di-tert-butyl-3,3'-(1,1'-dimethyleneferrocenyl)-diimidazol-2-ylidene. J Organomet Chem 690: 653-658.
- Viciano M, Mas-Marzá E, Poyatos M, Sanaú M, Crabtree RH, et al. (2005) An N-Heterocyclic Carbene/Iridium Hydride Complex from the Oxidative Addition of a Ferrocenyl-Bisimidazolium Salt: Implications for Synthesis. Angew Chem Int Ed 44: 444-447.
- Horvath U, Bentivoglio G, Hummel M, Schottenberger H, Wurst K, et al. (2008) A cytotoxic bis(carbene)gold(I) complex of ferrocenyl complexes: synthesis and structural characterisation. New J Chem 32: 533-539.
- Seo H, Kim BY, Lee JH, Park HJ, Son SU, et al. (2003) Synthesis of Chiral Ferrocenyl Imidazolium Salts and Their Rhodium(I) and Iridium(I) Complexes. Organometallics 22: 4783-4791.
- Nyamori V (2006) PhD Thesis. Nelson Mandela Metropolitan University, South Africa.
- Vogel AI (1989) Vogel's Textbook of Practical Organic Chemistry. 5th edn. In: Furniss BS, Hannaford AS, Smith PWG, Tatchell AR (eds). Longman, Essex.
- Oxford Diffraction (2006) CrysAlisPro. Oxford Diffraction Ltd., Abingdon, England.
- Sheldrick GM (2008) A short history of SHELX. Acta Cryst A 64: 112-122.
- Farrugia LJ (1997) ORTEP-3 for Windows - a version of ORTEP-III with a Graphical User Interface (GUI). J Appl Cryst 30: 565.
- Macrae CF, Edgington PR, MacCabe P, Pidcock E, Shields GP, et al. (2006) Mercury: visualization and analysis of crystal structures. J Appl Cryst 39: 453-457.

Citation: Onyancha D, McClelland C, Gerber T (2016) Synthesis, Characterisation and X-Ray Structure of Ferrocenyl N-Heterocyclic Carbene Complexes of Rhodium(I). Chem Sci J 7: 117. doi:10.4172/2150-3494.1000117

OMICS International: Publication Benefits & Features

Unique features:

- Increased global visibility of articles through worldwide distribution and indexing
- Showcasing recent research output in a timely and updated manner
- Special issues on the current trends of scientific research

Special features:

- 700 Open Access Journals
- 50,000 Editorial team
- Rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus, Google Scholar etc.
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: <http://www.omicsgroup.org/journals/submission>